Your browser doesn't support javascript.
loading
A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS).
Griffiths-Jones, Deborah J; Garcia, Yvonne Sylvestre; Ryder, W David; Pauling, John D; Hall, Frances; Lanyon, Peter; Bhat, Smita; Douglas, Karen; Gunawardena, Harsha; Akil, Mohammed; Anderson, Marina; Griffiths, Bridget; Del Galdo, Francesco; Youssef, Hazem; Madhok, Rajan; Arthurs, Barbara; Buch, Maya; Fligelstone, Kim; Zubair, Mohammed; Mason, Justin C; Denton, Christopher P; Herrick, Ariane L.
Afiliação
  • Griffiths-Jones DJ; Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK.
  • Garcia YS; Manchester Clinical Trials Unit, The University of Manchester, Manchester, UK.
  • Ryder WD; Manchester Clinical Trials Unit, The University of Manchester, Manchester, UK.
  • Pauling JD; Department of Rheumatology, Royal United Hospitals Bath NHS Trust, Bath, UK.
  • Hall F; Department of Rheumatology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Lanyon P; Department of Rheumatology, Nottingham University Hospitals NHS Trust, and Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK.
  • Bhat S; Department of Rheumatology, Ninewells Hospital and Medical School, Dundee, UK.
  • Douglas K; Department of Rheumatology, Dudley Group NHSFT, Dudley, UK.
  • Gunawardena H; Rheumatology Department, North Bristol NHS Trust, and Academic Rheumatology, University of Bristol, Bristol, UK.
  • Akil M; Department of Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Anderson M; Lancaster Medical School, Faculty of Health and Medicine, Lancaster University, Lancaster and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Griffiths B; Department of Rheumatology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Del Galdo F; NIHR Biomedical Research Centre and Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
  • Youssef H; Department of Rheumatology, Aberdeen Royal Infirmary, Aberdeen, UK.
  • Madhok R; Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, UK.
  • Arthurs B; Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK.
  • Buch M; Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK.
  • Fligelstone K; NIHR Manchester Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Zubair M; Royal Free Hospital, London, UK.
  • Mason JC; Research Governance and Integrity, The University of Manchester, Manchester, UK.
  • Denton CP; National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, UK.
  • Herrick AL; Centre for Rheumatology, UCL Division of Medicine, Royal Free Campus, London, UK.
Rheumatology (Oxford) ; 62(9): 3133-3138, 2023 09 01.
Article em En | MEDLINE | ID: mdl-36637209
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerodermia Difusa / COVID-19 Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerodermia Difusa / COVID-19 Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido